Phase 2 Clinical Trial Examines the Efficacy of a Novel Psychedelic for the Treatment of Postpartum Depression
Individuals with postpartum depression are being recruited for a clinical trial of a novel psychedelic compound, RE104.
Individuals with postpartum depression are being recruited for a clinical trial of a novel psychedelic compound, RE104.
Longer-term studies supporting the safety and efficacy of TMS during pregnancy are needed.
There is a wide range of barriers across multiple levels--individual, healthcare professional, interpersonal, organizational, political, and societal.
Further studies are needed to determine whether ketamine and esketamine are effective for the treatment of postpartum depression.
This review and meta-analysis reviews the effectiveness of cognitive behavioral therapy and mindfulness interventions for depression, anxiety, and cognitive functioning in women undergoing menopausal transition. Â
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on access to perinatal mental healthcare with Ob.Gyn News on May 23, 2024.
A growing body of literature supports the reproductive safety of stimulants in pregnant women and suggests that not treating may have negative consequences for the mother and her child.
This preliminary study demonstrates the potential benefits of increasing the dosage of psychostimulant medication premenstrually in women with ADHD who experience premenstrual worsening of ADHD and mood symptoms.
MamaLift Plus is a prescription-only digital therapeutic intervention for the treatment of mild to moderate postpartum depression using several different neurobehavioral interventions.
In this large cohort study analyzing data from publicly insured Medicaid beneficiaries, the overall risk of malformations was lower with buprenorphine than with methadone.